SCHEMBL448143

SCHEMBL448143

Cc1cc(C)c(B(O)O)c(C)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 2/20 0.43
LPL P06858 1/20 0.43
LIPG Q9Y5X9 1/20 0.43
TP53 P04637 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
RAPGEF4 Q8WZA2 3/20 0.39
ALDH1A1 P00352 2/20 0.39
GAA P10253 2/20 0.39
KDM4E B2RXH2 1/20 0.39
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.39
ORAI1 Q96D31 1/20 0.38
ORAI2 Q96SN7 1/20 0.38
ORAI3 Q9BRQ5 1/20 0.38
TRPV6 Q9H1D0 1/20 0.38
CYP1A2 P05177 1/20 0.37
CYP2A6 P11509 1/20 0.37
ACHE P22303 2/20 0.36
POLB P06746 1/20 0.35
TSHR P16473 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24840473 0.85 ACHE (0.46) CA2LPLLIPGTP53TDP1
SCHEMBL13209189 0.83 KDM4E (0.32) CA2LPLLIPGTP53TDP1
SCHEMBL815941 0.82 RAPGEF4 (0.39) CA2LPLLIPGTP53TDP1
SCHEMBL13084437 0.80 CYP3A4 (0.48) ALDH1A1GAAKDM4ELMNAMAPT
SCHEMBL9945964 0.80 RAPGEF4 (0.38) CA2LPLLIPGTP53TDP1
SCHEMBL446622 0.79 ESR2 (0.47) CA2ALDH1A1LMNACYP1A2CYP2A6
SCHEMBL2869340 0.79 ACHE (0.46) ALDH1A1KDM4EMAPTORAI1ORAI2
SCHEMBL29760877 0.79 ACHE (0.46) ALDH1A1KDM4EMAPTORAI1ORAI2
SCHEMBL14234579 0.79 KMT2A (0.36) CA2RAPGEF4ALDH1A1GAAKDM4E
SCHEMBL2147169 0.78 ENPP2 (0.40) CA2LPLLIPGRAPGEF4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 940 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250194617-A1 Materials and Methods for Extending Shelf-Life of Foods JP LABORATORIES, INC. 2025-06-19 US claimed
US-20250169514-A1 Materials and Methods for Extending Shelf-Life of Foods JP LABORATORIES, INC. 2025-05-29 US claimed
CN-118307532-A N2 substituted triazole-oxazoline chiral compound and preparation method and application thereof 吉林大学 2024-07-09 CN claimed
CN-113444125-B Phosphoramidite ligand, preparation method thereof and application thereof in asymmetric carbonylation reaction 西北大学 2024-01-26 CN claimed
US-20230380457-A1 Materials and Methods for Extending Shelf-Life of Foods JP LABORATORIES, INC. 2023-11-30 US claimed
EP-4280882-A2 MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS JP LABORATORIES, INC. (US) 2023-11-29 EP claimed
US-20230363426-A1 Materials and Methods for Extending Shelf-Life of Foods JP LABORATORIES, INC. 2023-11-16 US claimed
US-11793220-B2 Materials and methods for extending shelf-life of foods JP LABORATORIES, INC. (US) 2023-10-24 US claimed
CN-116916755-A Materials and methods for extending the shelf life of food products JP实验室公司 2023-10-20 CN claimed
CN-110372756-B Bivalent platinum complex and preparation method and application thereof 南京工业大学 2023-08-29 CN claimed
US-9362122-B2 Process for contact doping YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2016-06-07 US claimed
US-8361484-B2 Polymer systems for lung volume reduction therapy AERIS THERAPEUTICS, INC. (US) 2013-01-29 US claimed
WO-2012137211-A1 PROCESS FOR CONTACT DOPING YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2012-10-11 WO claimed
US-20100040538-A1 Polymer Systems for Lung Volume Reduction Therapy CANADIAN IMPERIAL BANK OF COMMERCE (CA) 2010-02-18 US claimed
EP-2059227-A2 POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY Aeris Therapeutics, Inc. (US) 2009-05-20 EP claimed
WO-2008039827-A2 POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY AERIS THERAPEUTICS, INC. (US) 2008-04-03 WO claimed
US-6800784-B1 REACTING AROMATIC COMPOUND CARRYING AT LEAST ONE AMINO GROUP AND LEAVING GROUP WITH ARYLBORONIC ACID OR DERIVATIVE THEREOF, IN AQUEOUS MEDIUM, AND IN PRESENCE OF EFFECTIVE QUANTITY OF PALLADIUM CATALYST RHODIA CHIMIE (FR) 2004-10-05 US claimed
US-6590100-B2 Reacting an aromatic compound bearing a leaving group and an arylboronic acid and/or its derivatives in the presence of a base and an effective amount of a nickel catalyst RHODIA CHIMIE (FR) 2003-07-08 US claimed
US-20020173652-A1 Process for preparing a polyaromatic compound SHASUN PHARMA SOLUTIONS, INC. 2002-11-21 US claimed
WO-1995005081-A1 BIOCIDAL COMPOSITIONS CONTAINING ORGANOBORON COMPOUNDS U.S. BORAX INC. (US) 1995-02-23 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100040538-A1 Polymer Systems for Lung Volume Reduction Therapy GFER, MUC1, CTH CA2 2856/4885LPL 3998/4885LIPG 1131/4885
US-20020173652-A1 Process for preparing a polyaromatic compound PAH, ALK, ITPA CA2 2394/4885LPL 4812/4885LIPG 4623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.